Clinical Cancer Research · 2012 · 56 citations · 28 references
MedicineGeneticsOncologyCancer GeneticsMolecular OncologyTumor ProgressionAndrogen Deprivation TherapyBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyEndocrine Tumor PrognosisMolecular Tumor ProfilingProstate CancerGenetic Susceptibility To Prostate CancerHost Genetic PolymorphismsMolecular Prognostic MarkersPrognosis Of Prostate DiseaseProstate Cancer PrognosisSingle-nucleotide PolymorphismsSteroidogenic Enzyme GenesTag Single Nucleotide Polymorphisms
PURPOSE: Prostate cancer is a heterogeneous genetic disease, and molecular methods for predicting prognosis in patients with aggressive form of the disease are urgently needed to better personalize treatment approaches. The objective was to identify host genetic variations in candidate steroidogenic genes affecting hormone levels and prostate cancer progression. EXPERIMENTAL DESIGN: The study examined two independent cohorts composed of 526 Caucasian men with organ-confined prostate cancer and 601 Taiwanese men on androgen-deprivation therapy. Caucasians were genotyped for 109 haplotype-tagging single-nucleotide polymorphisms (SNP) in CYP17A1, ESR1, CYP19A1, and HSD3B1, and their prognostic significance on disease progression was assessed using Kaplan-Meier survival curves and Cox regression models. Positive findings, including previously identified SRD5A1, SRD5A2, HSD17B2, HSD17B3, and HSD17B12 polymorphisms, were then explored in Taiwanese men (n = 32 SNPs). The influence of positive markers on the circulating hormonal levels was then appraised in Caucasians using specific and sensitive mass spectrometry-based methods. RESULTS: After adjusting for known risk factors, variants of CYP17A1 (rs6162), HSD17B2 (rs4243229 and rs7201637), and ESR1 (rs1062577) were associated with progressive disease in both cohorts. Indeed, the presence of these variations was significantly associated with progression in Caucasians (HR, 2.29-4.10; P = 0.0014-2 × 10(-7)) and survival in Taiwanese patients [HR = 3.74; 95% confidence interval (CI): 1.71-8.19, P = 0.009]. Remarkably, the CYP17A1 rs6162 polymorphism was linked to plasma dehydroepiandrosterone-sulfate (DHEA-S) levels (P = 0.03), HSD17B2 rs7201637 with levels of dihydrotestosterone (P = 0.03), and ESR1 rs1062577 with levels of estrone-S and androsterone-glucuronide (P ≤ 0.05). CONCLUSION: This study identifies, in different ethnic groups and at different disease stages, CYP17A1, HSD17B2, and ESR1 as attractive prognostic molecular markers of prostate cancer progression.
28
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Howard I. Scher, Tomasz M. Beer, Celestia S. Higano et al. · The Lancet · 2010 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +13